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ARTICLE
Epidemiology
Predictive value of inﬂammatory markers for cancer diagnosis
in primary care: a prospective cohort study using electronic
health records
Jessica Watson 1,2, Chris Salisbury1,2, Jonathan Banks1,2, Penny Whiting1,2 and Willie Hamilton3
BACKGROUND: Early identiﬁcation of cancer in primary care is important and challenging. This study examined the diagnostic
utility of inﬂammatory markers (C-reactive protein, erythrocyte sedimentation rate and plasma viscosity) for cancer diagnosis in
primary care.
METHODS: Cohort study of 160,000 patients with inﬂammatory marker testing in 2014, plus 40,000 untested matched controls,
using Clinical Practice Research Datalink (CPRD), with Cancer Registry linkage. Primary outcome was one-year cancer incidence.
RESULTS: Primary care patients with a raised inﬂammatory marker have a one-year cancer incidence of 3.53% (95% CI 3.37–3.70),
compared to 1.50% (1.43–1.58) in those with normal inﬂammatory markers, and 0.97% (0.87–1.07) in untested controls. Cancer risk
is greater with higher inﬂammatory marker levels, with older age and in men; risk rises further when a repeat test is abnormal but
falls if it normalises. Men over 50 and women over 60 with raised inﬂammatory markers have a cancer risk which exceeds the 3%
NICE threshold for urgent investigation. Sensitivities for cancer were 46.1% for CRP, 43.6% ESR and 49.7% for PV.
CONCLUSION: Cancer should be considered in patients with raised inﬂammatory markers. However, inﬂammatory markers have a
poor sensitivity for cancer and are therefore not useful as ‘rule-out’ test.
British Journal of Cancer https://doi.org/10.1038/s41416-019-0458-x
BACKGROUND
Cancer is common—affecting 50% of the UK population during
their lifetime.1 Early diagnosis is important, with delayed
diagnosis associated with more advanced stage at diagnosis
and decreased survival.2,3 Cancer diagnosis in primary care can
be challenging; many of the early symptoms are non-speciﬁc
and can be difﬁcult to differentiate from the symptoms of
common benign conditions. When patients present with high-
risk symptoms, GPs in England can refer via urgent cancer
referral pathways, but many patients with cancer present with
low-risk (but not no-risk) symptoms.4–6 GPs need to triage
patients with low-risk symptoms to identify those needing
further investigations, using additional ‘clues’ from history,
examination and investigations. One triaging tool increasingly
used in clinical practice is inﬂammatory marker tests, with the
three most commonly used in UK practice being C-reactive
protein (CRP), erythrocyte sedimentation rate (ESR) and plasma
viscosity (PV). These are often performed as a ‘rule-out’ test by
clinicians trying to exclude serious underlying disease, including
cancer.7 This practice is largely unsupported by evidence;
inﬂammatory markers are not recognised within current guide-
lines for cancer diagnosis,8 with the exception of myeloma,
where ﬁrst line tests include ESR or PV. Cohort studies in the
general population (irrespective of symptoms) have examined
the association between raised CRP and risk of future cancer,9–11
including meta-analyses of the risk of future colorectal,12,13
lung,14 ovarian15 and breast cancer.16,17 However, the associa-
tions are not strong enough to be clinically useful for
identiﬁcation of symptomatic cancer. Studies of speciﬁc cancers
in symptomatic primary care patients have reported an
association between raised inﬂammatory markers for bladder
and kidney cancers, Hodgkin and non-Hodgkin lymphomas, plus
myeloma, albeit with very low positive predictive values (PPVs)
for a raised inﬂammatory marker result.18–23
To our knowledge, there have been no studies to measure the
overall clinical utility of inﬂammatory markers for cancer
diagnosis in primary care. This study aimed to address this
omission by determining the predictive value of inﬂammatory
markers for cancer diagnosis in primary care; measuring cancer
incidence in those with normal and raised inﬂammatory markers
and calculating measures of diagnostic accuracy.
METHODS
Data sources
This was a prospective cohort study of UK primary care patients
using routinely collected data from electronic health records in
the Clinical Practice Research Datalink (CPRD). This contains
anonymised, coded data on primary care consultations, labora-
tory results and referrals.
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Participants
Participants were 160,000 patients, aged ≥18, of either sex, who
had a primary care inﬂammatory marker blood test (CRP, ESR or
PV) taken in 2014, selected at random by CPRD.
A comparison sample of 40,000 patients with no inﬂammatory
markers taken during 2014 was matched by age (within 5-year
bands), sex and practice to a random subset of 40,000 patients
from the inﬂammatory marker test group. This group, whilst not
needed for the diagnostic test accuracy evaluation, allows us to
compare the incidence of disease in the tested vs. untested
populations. Given that inﬂammatory marker tests are more likely
to be done in symptomatic patients at higher risk of cancer than
the general population, this gives us an indication of the
diagnostic accuracy of clinicians’ gestalt judgement to perform
an inﬂammatory marker test.
Linked data from the English Cancer Registry was obtained by
the CPRD for 110,245 patients. Patients in whom it was not
possible to obtain linked data were resident outside England,
lacked a valid NHS identiﬁer, were registered at a GP practice
which had not consented to linkage or were individuals who had
personally dissented from linkage.
Patients with a record of cancer in CPRD or the cancer registry
in the 2-year period before the index date were excluded (n=
4489), as were patients who had missing or spurious inﬂammatory
marker test results (n= 662).
Index tests
Three inﬂammatory marker tests were analysed: CRP, ESR and PV.
The index date was deﬁned as the ﬁrst date of inﬂammatory
marker blood testing in 2014; controls were allocated the same
index date as their matched case. As different laboratories use
different thresholds to deﬁne abnormality, we used the mean
upper limit of normal from laboratories within our study to deﬁne
a raised inﬂammatory marker. For CRP this mean was 6.8 mg/l,
therefore we rounded to a conservative threshold of 7 mg/l. For
PV the upper limit of normal was 1.72 mPa.s. For ESR, we used the
mean reported upper limit of normal, stratiﬁed by gender and in
10-year age bands, which varied from 11mm/h for women under
40, to 23mm/h for men over 80 (see supplementary table 1). For
those with the same inﬂammatory marker test coded more than
once on the same day (n= 231), the highest value was retained.
For patients with more than one type of inﬂammatory marker on
the same day a binary variable was generated for ‘any raised
inﬂammatory marker’, which was positive if any of CRP, PV or ESR
were raised.
Outcome variables
The primary outcome was the one-year cancer incidence; we also
examined two-year incidence, lest there be a delayed effect. All
new cancer diagnoses, excluding benign and in situ cancers and
non-melanomatous skin cancers, were identiﬁed by searching the
CPRD records for any of the 2120 cancer-related codes (available
from the authors on request). This code list has been developed
using published methods24 and validated in several studies: it is
collated into 22 common cancer sites. New cancer diagnoses were
also extracted from the cancer registry by CPRD staff. Patients
were included as having cancer if a diagnosis was recorded in
either CPRD or the cancer registry, with the earliest record of
cancer assigned to be the date of diagnosis.
In order to identify the main symptoms associated with
inﬂammatory marker testing, we searched the CPRD for codes in
the 28 days prior to and including the index date. We retained the
200 most frequently occurring codes in those with raised
inﬂammatory markers, normal inﬂammatory markers and untested
controls. After removing non-clinical administrative codes we used
frequency counts to identify the most commonly occurring
symptoms, categorised according to the International Classiﬁca-
tion of Primary Care.25 We then used methods described
previously24 to generate complete code lists for each of these
symptoms.
Sample size calculation
Assuming a 2:1 ratio of normal to raised inﬂammatory markers, to
detect an increase of 0.2% cancer incidence in the test positive
compared to test negative group, assuming a baseline (test
negative) condition incidence of 0.8% requires a sample size of
77,577 for 80% power and alpha= 0.05. The CPRD were willing to
offer a sample size of 160,000 which provided a power of 98% for
the same estimated differences and allowed subgroup analyses.
The focus of the study was cancer outcomes in those with
inﬂammatory marker testing, therefore the untested group—used
as a benchmark for the tested group—was deliberately kept small
to ensure maximum power in the main study.
Analysis
The primary analysis reported the one-year cancer incidence
(hereafter referred to as ‘cancer incidence’) for patients with raised
vs. normal inﬂammatory markers, and vs. untested patients. For
those with raised inﬂammatory markers, this is equivalent to the
PPV. Sub-analyses stratiﬁed cancer incidence by gender and age in
10-year bands. We also stratiﬁed analysis according to whether
multiple inﬂammatory markers showed concordant or discordant
results, whether repeat inﬂammatory markers were normal or
abnormal, and according to symptoms recorded in CPRD in the
28 days prior to testing. We used logistic regression to examine
the dose-response relationship between CRP, ESR and PV test
results as continuous variables, and cancer diagnosis as a binary
variable, also generating a receiver-operating characteristic (ROC
curve). Logistic regression was also used to generate diagnostic
odds ratios (DOR), which were adjusted for age and gender.
Several sensitivity analyses in subgroups were performed; exclud-
ing those with <1 year follow-up in CPRD (for example patients
moving practice), excluding those with pre-existing autoimmune
disease and recent infections (who might be expected to have
tests for monitoring purposes) and excluding those with myeloma
(as this is already known to have a strong association with raised
inﬂammatory markers). We also performed a sensitivity analysis
using the laboratory’s own upper limit of normal rather than our
own derived thresholds. A ﬁnal sensitivity analysis explored the
impact of restricting analysis only to those patients eligible for
cancer registry linkage.
The reporting of this study conforms to the STARD26 and
RECORD27 statements. Analysis was performed using Stata15,
using the module DIAGT28 to calculate summary statistics from
2 × 2 tables including sensitivity, speciﬁcity, PPV and negative
predictive value (NPV).
RESULTS
After exclusions (see Fig. 1), the inﬂammatory marker cohort
contained 155,646 patients; of these 111,440 (71.6%) had a CRP
test, 90 478 (58.1%) had an ESR test, and 15,670 (10.1%) had a PV
test. 61,545 (39.5%) had more than one test performed together
on the index date, mostly CRP and ESR (50 522), followed by CRP
and PV (10 494). 46,092 (29.6%) of the tested cohort had at least
one raised inﬂammatory marker.
Table 1 shows the gender, age and cancer incidence of the
cohort, grouped by test result. The overall incidence of cancer for
those with a raised inﬂammatory marker was 3.53% (95% CI
3.37–3.70), compared to 1.50% (1.43–1.58) with normal inﬂamma-
tory markers (p < 0.001). The untested cohort had a cancer
incidence of 0.97% (0.87–1.07%). Most cancer diagnoses were
made within 1 year of testing, with no evidence of signiﬁcantly
increased cancer risk in the second year after a raised
inﬂammatory marker compared to untested controls. For each
of the three tests, sensitivities, speciﬁcities, PPV, AUC and DOR for
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a positive result are shown in Table 2. Figure 2 shows cancer
incidence according to test results in a ﬂowchart for CRP, the most
frequently used of the three inﬂammatory marker tests. A logistic
regression model containing age and gender had an AUC of 0.736,
compared to 0.747 for a full model containing age, gender and
CRP test result as a continuous variable (p < 0.001); 0.759 with age,
gender and ESR (p < 0.001); and 0.760 with age gender and PV
(p < 0.001).
Sensitivity analyses are shown in supplementary table 2; these
gave minor differences in results which were not clinically
signiﬁcant. Restricting analysis to the 110,245 patients eligible
for Cancer Registry linkage increased cancer incidence marginally
to 3.82% (3.58–4.05) in the raised inﬂammatory marker group,
1.63% (1.53–1.73) in the normal inﬂammatory marker group and
1.04% (0.90–1.17) in the untested group.
Inﬂammatory marker levels
The incidence of cancer increased with rising inﬂammatory
markers with a dose-response relationship; see supplementary
Fig. 1. Out of 506 people with ESR ≥ 100, 69 (13.6%) developed
cancer in 1 year; with CRP ≥ 100 (n= 1983), 135 (6.81%) developed
cancer; with PV ≥ 2.0 mm/h (n= 342), 31 (9.06%) developed
cancer.
Repeat testing
When patients with a raised inﬂammatory marker (n= 46,092) had
a second inﬂammatory marker test taken within 90 days (n=
13,873), the cancer incidence was greatest if the second test result
was further increased, at 6.86% (5.73–7.99) for CRP, 5.04%
(4.01–6.08) for ESR and 4.13% (2.00–6.26) for PV. If the second
test was lower than the ﬁrst, but still above the normal range, the
cancer incidence was 4.35% (3.66–5.04) for CRP, 3.55% (2.86–4.24)
for ESR and 3.28% (1.79–4.78) for PV. If the repeat test was normal
the cancer incidence fell to 1.98% (1.49–2.47) for CRP, 2.49%
(1.73–3.26) for ESR, and 1.32% (0.34–2.29) for PV. This is shown in
Fig. 2 for the most frequently used inﬂammatory marker, CRP.
Multiple inﬂammatory marker tests
For the 61,545 who had more than one inﬂammatory marker test
done together, if both were normal (n= 39 368; 64.0%), the cancer
incidence was 1.28% (1.17–1.39), with one raised and the other
normal (n= 13 472; 21.9%) the cancer incidence was 2.27%
Table 1. Demographics and cancer incidence by test result
Raised inﬂammatory markersa Normal inﬂammatory markersb Untested
Number of patients (n) 46 092 109 554 39 131
Female (%) 64.9 61.1 62.0
Age, years (mean, IQR) 61.9 (46.5–75.3) 53.9 (39.9–68.5) 56.2 (41.6–70.7)
Cancers diagnosed in 1 year (n) 1 629 1 648 379
1-year cancer incidence % (95% CI)c 3.53 (3.37–3.70) 1.50 (1.43–1.58) 0.97 (0.87–1.07)
Second year cancer incidence % (95% CI) 1.07 (0.97–1.16) 0.77 (0.72–0.82) 0.96 (0.86–1.05)
aOne or more inﬂammatory marker raised
bAll inﬂammatory markers tested normal
cEquivalent to positive predictive values (PPV) for the test positive group
Identified by CPRD
n = 199,928
Cohort only
n = 116,708
Tested cohort
(>18yo, inflammatory marker
test in 2014)
n = 160,000
Cohort only
n = 120,000
Subset for matching
n = 40,000
Age, sex and
practice matching Matched untested
n = 39,928*
Matched tested
n = 38,868
Matched untested
n = 39,131
Untested cohort
n = 39,131
Exclusions:
Results of index test
missing n = 522
Pre-existing cancer n = 2769
Spurioustest result n = 1
Total n = 3292 (2.74%)
Exclusions:
Results of index test
missing n = 138
Pre-existing cancer n = 923
Spurioustest result n = 1
Total n = 1062 (2.66%)
Exclusions:
Pre-existing cancer n = 797
Total n = 797 (2.00%)
Total tested cohort n = 155,646
CRP n = 111,440 (716%)
ESR n = 90,478 (58.1%)
PV n = 15,670(10.1%)
Fig. 1 Flowchart showing participants and exclusions. *Matched untested group consists of 39,928 because from the 40,000 patients from the
cohort who were randomly selected for matching, 72 had no suitable age, sex and practice matched control
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(2.02–2.52), if both were raised (n= 8 705; 14.1%) then cancer
incidence was 4.71% (4.26–5.16).
Effects of age and gender
Breakdown by age and gender (Fig. 3) shows that cancer
incidence increases with age and is higher in men, exceeding
the NICE 3% threshold for urgent cancer referral for men over 50
and women over 60 years with a raised inﬂammatory marker, who
have a cancer incidence of 6.44% (6.00–6.88) and 4.22%
(3.90–4.45) respectively. For women under the age of 60 with a
raised inﬂammatory marker, cancer incidence was 1.20%
(1.03–1.37); for men under 50 it was 1.03% (0.72–1.33). Patients
with normal inﬂammatory markers have a cancer incidence which
exceeds that of untested controls and national cancer registry
rates but is lower than the raised inﬂammatory marker group. In
particular, men over 60 with normal inﬂammatory markers have a
cancer incidence which exceeds the NICE 3% threshold.
Cancer sites
The types of cancer are shown in Table 3; the cancer sites broadly
reﬂect overall cancer incidence in 2014 from National Cancer
Registry ﬁgures, apart from breast cancer and prostate cancer,
which are notably less frequent in the raised inﬂammatory marker
group. Myeloma contributed only 45 out of 2145 cancers in the
raised inﬂammatory marker group; sensitivity analysis demon-
strated minimal difference in overall results when these were
excluded (cancer incidence in the raised inﬂammatory marker
group 3.45% excluding myeloma, vs. 3.53% overall; supplemen-
tary table 2).
Symptoms
Supplementary table 3 shows the most frequently occurring
symptoms in the 28 days before the index date, and cancer
incidence in patients with normal and raised inﬂammatory
markers with these symptoms. None of the symptoms identiﬁed
are high-risk symptoms warranting urgent cancer referrals under
current NICE guidelines. The commonest symptoms were
abdominal symptoms, joint symptoms, infective symptoms,
and non-speciﬁc symptoms. Cancer incidence was signiﬁcantly
higher for those with a raised vs. normal inﬂammatory markers in
all symptom subgroups except patients with throat symptoms.
PPVs were >5% for those with raised inﬂammatory markers
associated with cough, back pain, nausea and vomiting, and
chest pain.
DISCUSSION
This is the ﬁrst study looking at the overall incidence of cancer in
primary care following inﬂammatory marker blood testing.
Primary care patients with a raised inﬂammatory marker have an
overall one-year cancer incidence of 3.53%, more than twice the
risk in those with a normal test. Cancer incidence rises with rising
levels of inﬂammatory markers and is higher still if a second test
shows persistent raised inﬂammatory markers. However, inﬂam-
matory markers are not a useful rule-out test for cancer, as with a
sensitivity of 46.1% for CRP, 43.6% for ESR and 49.7% for PV,
roughly half of the tested patients with cancer had a normal
inﬂammatory marker test in the 1 year before diagnosis. Patients
with normal inﬂammatory markers have a cancer incidence of
1.50%, higher than the untested group with 0.97% cancer
incidence; this is because the mere fact that a test has been
performed predicts cancer, and this increased risk is only partially
mitigated by a negative test result. Importantly, women under 60
and men under 50 with raised inﬂammatory markers have a risk of
cancer below 3% so investigations for cancers would not usually
be warranted.
Table 2. Performance characteristics of inﬂammatory markers tests for cancer
True
positives
(n)
False
positives
(n)
True
negatives
(n)
False
negatives
(n)
Sensitivity Speciﬁcity AUCa DORb
(unadjusted)
DOR (adjusted
for age+
gender)
CRP
(n= 111,440)
1077 26,883 82,219 1261 46.1% (44.0–48.1) 75.4% (75.1–75.6) 0.641 (0.63–0.65) 2.29* (2.12–2.46) 1.79* (1.66–1.93)
ESR
(n= 90,478)
810 21,628 66,993 1047 43.6% (41.4–45.9) 75.6% (75.3–75.9) 0.644 (0.63–0.66) 1.98* (1.83–2.15) 1.75* (1.61–1.90)
PV
(n= 15,670)
153 4289 11,073 155 49.7% (44.0–55.4) 72.1% (71.4–72.8) 0.631 (0.60–0.66) 1.69* (1.43–1.99) 1.45* (1.22–1.71)
*p < 0.0001
aArea under receiver operator curve
bDiagnostic odds ratio
Untested (n = 39,131)
Cancer incidence 0.97%
(95% CI 0.87–1.07)
CRP tested (n = 111,440)
Cancer incidence 2.10%
(95% CI 2.01–2.18)
CRP negative (n = 83,480)
Cancer incidence 1.51%
(95% CI 1.43–159)
CRP positive (n = 27,960)
Cancer incidence 3.85%
(95% CI 3.63–4.08)
Repeat CRP normal (n = 3130)
Cancer incidence 1.98%
(95% CI 1.49–2.47)
No repeat CRP test (n = 19,536)
Cancer incidence 3.77%
(95% CI 3.50–4.03)
Repeat CRP stable/falling
(n = 3355)
Cancer incidence 4.35%
(95% CI 3.66–5.04)
Repeat CRP rising (n = 1939)
Cancer incidence 6.86%
(95% CI 5.73–7.99)
Fig. 2 Flowchart of one-year cancer incidence according to CRP test results. The right-hand column shows cancer incidence according to
repeat test result; deﬁned as the ﬁrst CRP test performed in the 3 months following the index date
Predictive value of inﬂammatory markers for cancer diagnosis in primary. . .
J Watson et al.
4
Strengths and weaknesses of the study
The main strengths of this study are the large sample size and the
setting in primary care, which is where the initial suspicion of
cancer usually arises. Studies using CPRD are reliant on the quality
of data recording, but as blood test results are electronically
transmitted to GP records this reduces the risk of missing data or
bias. GPs are likely to record diagnoses of cancer carefully, and the
use of Cancer Registry Data also improved outcome ascertainment
in the linked practices.
The main weakness of the study is the lack of full data on the
reason for inﬂammatory marker testing. As a result, the sample is
heterogenous, and will include patients with clinically apparent
infections or autoimmune conditions. Sensitivity analysis, exclud-
ing patients with pre-existing autoimmune diseases and infections
conﬁrms that this does not make a clinically signiﬁcant difference
to the cancer incidence ﬁgures reported here. The beneﬁt of
looking at all tests, rather than restricting analysis to tests done for
speciﬁc indications, is that it reﬂects the way that inﬂammatory
markers are used in real-life clinical practice. Although GPs may
not be looking for cancer speciﬁcally when they request
inﬂammatory markers, they should consider the possibility of
cancer when interpreting test results.
The primary outcome, incidence of cancer at 1 year, is a
proxy measure for prevalence of cancer at the time of testing.
This period was chosen as a reasonable compromise between
identifying all cancers related to the raised inﬂammatory
marker, but ideally omitting cancers unrelated to the test.
Most of the cancers in the test positive group were identiﬁed
within 1 year, with no excess cancer risk in the second year
after testing. We could only obtain cancer registry data for ~55%
of our patients, as some CPRD regions are not yet linked to
cancer registry. We chose not to limit our analysis to only
practices with linked data, as this could introduce bias. Sensitivity
analysis restricting to only patients with cancer registry linkage
suggests that our overall PPV estimates may be small under-
estimates, due to small numbers of missing cancers in the
unlinked practices.
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Fig. 3 One-year incidence of cancer, stratiﬁed by age and gender. Red line, NCRAS, Cancer incidence from UK National Cancer Registration
and Analysis Service; green line, normal inﬂammatory markers, n= 109,554; blue line, raised inﬂammatory markers, n= 46,092; purple line,
untested, n= 39,131. Shaded areas= 95% conﬁdence intervals. The black line represents the 3% threshold used by NICE for urgent
investigation or referral
Table 3. Types of cancer diagnosed by gender in those with raised
inﬂammatory markers, compared to types of cancer diagnosed
nationally in England in 201435
Male Female
Raised
inﬂammatory
markers
National
incidence
Raised
inﬂammatory
markers
National
incidence
Cancer site % (n) % % (n) %
Bladder 3.91 (41) 4.14 1.59 (17) 1.56
Breast 0.19 (2) 0.22 15.78 (169) 31.56
Cervix – – 1.12 (12) 1.77
Head and neck 1.34 (14) 1.56 0.19 (2) 1.66
Kidney 3.82 (40) 3.79 2.80 (30) 2.34
Leukaemia 2.10 (22) 3.25 2.43 (26) 2.21
Lymphoma 2.29 (24) 4.94 3.08 (33) 4.07
Myeloma 2.58 (27) 1.72 1.68 (18) 1.41
Oesophagus 3.24 (34) 3.27 1.31 (14) 1.63
Pancreas 4.01 (42) 2.70 4.48 (48) 2.75
Stomach 1.81 (19) 2.32 2.15 (23) 1.26
Testis 0.19 (2) 1.34 – –
Uterus – – 3.64 (39) 5.27
Brain 1.43 (15) 1.59 1.12 (12) 1.23
Colorectal 12.69 (133) 12.46 12.98 (139) 10.43
Lung 17.56 (184) 13.34 14.75 (158) 11.86
Ovary 4.20 (45) 4.32
Oral 1.34 (14) 3.07 0.75 (8) 1.64
Melanoma 1.53 (16) 4.30 2.24 (24) 4.45
Prostate 14.98 (157) 26.35
Other 25.0 (262) 9.64 23.72 (254) 8.58
Total 100 (1074) 100 100 (1071) 100
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We chose to use a standardised deﬁnition of raised inﬂamma-
tory markers to aid interpretation and generalisability. This
conservative deﬁnition slightly reduced the proportion of test
results deﬁned as abnormal, but sensitivity analyses showed
minimal impact on overall results compared to laboratory
speciﬁed upper limits of normal. It is likely that the conservative
thresholds we used reﬂect real-life clinical practice, with clinicians
less likely to action peri-normal test results.
Our untested comparison group did not have inﬂammatory
marker testing in 2014 but could have had tests before or
afterwards; the alternative of selecting a comparison group never
to have had an inﬂammatory marker test was likely to introduce a
bias from particularly good health.
Comparison with previous literature
Several old studies have examined cancer risk in patients
with signiﬁcantly raised inﬂammatory markers. For example in a
cohort of 1004 hospital outpatients with an ESR > 100 mm/h, 17%
had malignancy,29 while in another hospital cohort 16% of those
with ESR > 100 mm/h had malignancy.30 In our cohort 13.6% of
those with ESR > 100 mm/h developed cancer in one year, the
slightly lower ﬁgure probably representing the primary care
setting. More recently, CRP and ESR have been evaluated as a tool
for predicting cancer in patients with non-speciﬁc symptoms
referred to Diagnostic Outpatient Clinics for rapid access to cancer
diagnostics in Denmark.31 In this setting cancer prevalence was
much higher at 19.8%; those with raised CRP had an odds ratio of
1.41 for cancer, after adjustment for age and sex, similar to our
adjusted DOR for raised CRP of 1.79. Our ﬁndings demonstrate
that this association exists, not only in the highly selected group of
patients referred with suspected cancer, but also in unselected
primary care patients, where the initial triaging and referral
decisions must be made. Although we found no evidence that
CRP, ESR or PV were superior to one another in relation to overall
cancer detection, this may not be true for all types of cancer; for
example recent studies have shown that ESR and PV are superior
to CRP for myeloma diagnosis.32 As myeloma is known to have a
strong association with raised inﬂammatory markers, it is perhaps
surprising that myeloma comprised only small proportion of the
overall cancers (<3%); when these were excluded from the
analysis the incidence of cancer in the raised inﬂammatory marker
cohort was 3.45%, compared to 3.53% overall.
Implications for clinical practice and research
Current UK NICE guidelines recommend urgent cancer referral
for any patient with a risk of cancer of 3% or higher,8 with studies
of patient preferences suggesting an even lower threshold of
1%.33 With overall PPVs of 3.53%, inﬂammatory markers may aid
earlier diagnosis of cancer. Inﬂammatory markers are not
currently part of NICE guidelines for cancer diagnosis, with the
exception of myeloma. Our ﬁndings suggest that, whilst not a
useful rule-out test, inﬂammatory markers may have a role as a
triage test in patients with ‘low-risk but not no-risk’ symptoms of
cancer.
Interpretation of inﬂammatory marker test results must take
into account the reasons for testing; if there is a clinically
obvious explanation for raised inﬂammatory markers from
history and examination, then further investigations for cancer
would not usually be appropriate. Women under 60 and men
under 50 with raised inﬂammatory markers have a risk of cancer
below the 3% threshold, and in the absence of other risk factors,
further investigations for cancers would not usually be
warranted. For older patients with unexplained raised inﬂam-
matory markers, our study supports a strategy of repeat testing,
with lower cancer incidence in those for whom the test returns
to normal, and higher cancer incidence in those with rising
inﬂammatory markers. Further investigations for cancer should
be considered in patients with persistent unexplained raised
inﬂammatory markers, particularly in older men, who are at
highest risk. With signiﬁcantly raised inﬂammatory markers,
especially if accompanied by ‘low-risk but not no-risk’ cancer
symptoms or signs, urgent investigation or referral may be
appropriate, without repeat testing. The range of possible
cancers is wide, so the choice of further investigations will vary
depending on the clinical history and examination ﬁndings;
recently introduced multidisciplinary diagnostic centres for
patients with non-speciﬁc but concerning symptoms,34 may be
appropriate if a clear source cannot be found. Excluding
myeloma is not sufﬁcient, as this only contributes a small
proportion of the cancers diagnosed in the raised inﬂammatory
marker cohort.
Although the PPVs from a raised inﬂammatory marker are
clinically signiﬁcant, inﬂammatory markers have poor sensitivity,
so cannot be used to rule-out cancer. This is discordant with
qualitative work suggesting that most doctors use inﬂammatory
markers as a rule out test.7 The clinical usefulness of this study is
therefore in guiding the clinical management of a patient with a
raised inﬂammatory marker, particularly when this has been used
as a non-speciﬁc test. Inﬂammatory markers should be used
judiciously for possible cancer, taking into account the risks of
false positives, which may generate anxiety, and false negatives,
which may generate inappropriate reassurance. Rather than
ruling cancer in or out deﬁnitively, inﬂammatory markers
function as a Bayesian test, with a positive result increasing the
risk of cancer, and negative results decreasing cancer risk.
Further research is needed to explore how inﬂammatory marker
blood test results, combined with other common blood tests,
such as platelet, haemoglobin and calcium levels, alongside
symptoms and signs, could generate prediction models with
increased accuracy, to improve the early diagnosis of cancer in
primary care.
CONCLUSIONS
Raised inﬂammatory markers are associated with cancer and may
predate the diagnosis by several months, especially in older
patients, male patients, and those with very high or persistent
abnormalities. Appropriate and timely investigation of patients
with raised inﬂammatory markers may help improve the early
detection of cancer. Inﬂammatory markers are not a useful rule-
out test for cancer.
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